Specialty Services

We offer unique, proprietary, and differentiated genomic tests in the following tumor types. We use blended technology platforms (microRNA, NGS, FISH, PCR, IHC) and customized scientific approaches for each tumor type in our offering.

Cancer Origin

A cutting-edge molecular test that identifies the primary origin of tumors. Measures just 64 microRNA biomarkers to identify 49 cancer origins. RosettaGX Cancer Origin provides a single answer with high sensitivity (90%) in the majority of cases, and never reports more than two possible answers.1

By selecting CORE, our lab will first run your sample using our RosettaGX Cancer Origin test. Once the primary tumor origin is identified, we will reflex to the next clinically appropriate assay in our portfolio.

Learn More

RosettaGX Reveal is a unique, proprietary microRNA-based assay for accurate thyroid nodule classification that has significant clinical and logistical benefits for Endocrinologists and the patients they treat.

Learn More
OncoGxOne · OncoGxLung

Our Next-Gen tests leverage Next-Generation Sequencing (NGS) technology for a comprehensive analysis of genomic information. OncoGxOne detects all currently known, clinically relevant alterations in 64 cancer genes, while OncoGxLung interrogates 5 genes associated with lung cancer targeted therapies

Learn More
FISH, PCR, IHC · OncoGxLung · mi-LUNG

Our comprehensive lung-specific menu includes mi-LUNG, a proprietary microRNA diagnostic test for differentiating the 4 main subtypes of lung cancer, plus OncoGxLung (utilizing NGS), and a full array of lung-specific biomarkers via FISH, PCR and IHC, including: ALK, ROS1, EGFR, KRAS, BRAF, RET, MET, FGFR1, and PD-L1.

Learn More

Our prostate portfolio of tests includes a proprietary analysis of the ERG gene by FISH, and in combination with PTEN by FISH, an overall prognostic assessment is provided which helps inform physicians on the most appropriate step forward: active surveillance or treatment.

Learn More
FGFR3 Urine · FGFR3 Tissue · UroVysion®

The urine-based FGFR3 mutation analysis helps identify low-grade, lower risk tumors.2 FGFR3 can also be ordered on tumor tissue for assistance with initial molecular grading of bladder cancer tumors. We also offer UroVysion, the first and only FDA-approved FISH test for initial bladder cancer diagnosis and follow up surveillance.

Learn More

We provide HER2 FISH testing combined with flexible tech-only ordering options, as well as IHC analysis of key biomarkers. These tests help enable the accurate assessment of a patient's status at the DNA and protein levels with a high degree of accuracy, guiding the most appropriate therapy decisions.

Learn More

We offer mi-KIDNEY, a molecular diagnostic test for kidney cancer that the 4 main histological types of primary kidney tumors: benign oncocytoma and the 3 most common subtypes of renal cell carcinomas (clear cell, papillary, and chromophobe). This assay may be helpful in reducing unnecessary surgeries if a definitive diagnosis can be obtained from a less invasive kidney biopsy.

Learn More


  1. Meiri E, Mueller W, Rosenwald S, et al. A Second-Generation microRNA-Based Assay for Diagnosing Tumor Tissue Origin. Oncologist. 2012;17(6):801-812.
  2. van Rhijn BW, van der Kwast TH, Liu L, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187:310-314